Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

This publication has 21 references indexed in Scilit:

• Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
  2003
• Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
  Annals of Oncology, 2003
• Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver
  Journal of Hepatology, 2001
• Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
  2001
• In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
  Clinical Pharmacology & Therapeutics, 2000
• Response and progression in recurrent malignant glioma
  Neuro-Oncology, 1999
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
  Journal of Clinical Investigation, 1998
• Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
  Cancer Chemotherapy and Pharmacology, 1997
• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
  Cancer Chemotherapy and Pharmacology, 1996
• The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs
  Biochemical Pharmacology, 1993